GE

Genovis ABFNSE Genovis Stock Report

Last reporting period 31 Dec, 2023

Updated 17 Oct, 2024

Last price

Market cap $B

0.149

Micro

Exchange

FNSE - First North Sweden

GENO.ST Stock Analysis

GE

Attractive

Based on Eyestock quantitative analysis, GENO.ST`s fundamental data and valuation indicate an investment grade of Attractive at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

128/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

681.7 %

Greatly undervalued

Market cap $B

0.149

Dividend yield

Shares outstanding

65.466 B

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

View Section: Eyestock Rating